Table 3.
Sustained Virologic Response Rates by Hepatitis C Virus Genotype and Direct-Acting Antiviral Regimen for Patients With Next-Generation Sequencing Data
| HCV Genotype | SVR, no./No. (%) | |||
|---|---|---|---|---|
| All DAA Regimens | NS3/NS5A DAA Regimens | NS5A/NS5B DAA Regimens | NS3/NS5A/NS5B DAA Regimens | |
| All | 119/144 (83) | 27/31 (87) | 67/87 (77) | 25/26 (96) |
| gt1a | 23/26 (88) | 3/5 (60) | 16/17 (94) | 4/4 (100) |
| gt1b | 16/17 (94) | 3/3 (100) | 8/9 (89) | 5/5 (100) |
| gt1l | 3/10 (30) | 1/1 (100) | 0/7 (0) | 2/2 (100) |
| gt3a | 7/9 (90) | 1/1 (100) | 6/8 (75) | 0 |
| gt4a | 25/27 (93) | 10/11 (91) | 12/13 (92) | 3/3 (100) |
| gt4d | 4/4 (100) | 0 | 3/3 (100) | 1/1 (100) |
| gt4r | 9/15 (60) | 2/2 (100) | 4/9 (44) | 3/4 (75) |
Abbreviations: DAA, direct-acting antiviral; gt, genotype; HCV, hepatitis C virus; SVR, sustained virological response.